Approximately 50% of high-grade serous ovarian cancer have homologous recombination deficiency including BRCA1 and/or BRCA2 mutations, with over 90% have TP53 mutations [52], and these mutations may lead to increased genetic instability, potentially increasing tumour immunogenicity. This evidence concerns the gene TP53 and neoplasm.